SSTR2 and neoplasm: The tumor-to-organ ratio of 177Lu-DOTATATE uptake showed at least a 2-fold increase in CI-994 (5 mg/kg)-treated QGP-1 tumors compared with control tumors, which represents a key feature for imaging contrast in SSTR2-targeted PRRT (Supplementary Fig. S4A and S4D).